[go: up one dir, main page]

AR132099A1 - Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo - Google Patents

Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo

Info

Publication number
AR132099A1
AR132099A1 ARP240100594A ARP240100594A AR132099A1 AR 132099 A1 AR132099 A1 AR 132099A1 AR P240100594 A ARP240100594 A AR P240100594A AR P240100594 A ARP240100594 A AR P240100594A AR 132099 A1 AR132099 A1 AR 132099A1
Authority
AR
Argentina
Prior art keywords
bispecific antibody
tumor antigen
pharmaceutical compositions
binds specifically
treating diseases
Prior art date
Application number
ARP240100594A
Other languages
English (en)
Inventor
Alina Valerevna Beliasnikova
Valentina Yurevna Filina
Anastasiya Andreevna Ivanova
Olga Leonidovna Kytmanova
Sergei Aleksandrovich Legotskii
Sergei Mikhalovich Krat
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2023105614A external-priority patent/RU2023105614A/ru
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR132099A1 publication Critical patent/AR132099A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo biespecífico que se une específicamente al CD3 y a un antígeno tumoral. La invención se refiere además a un ácido nucleico que codifica el anticuerpo biespecífico sujeto, un vector de expresión, una célula huésped para producir el anticuerpo biespecífico sujeto y un método para producir dicha célula, composiciones farmacéuticas que comprenden el anticuerpo biespecífico según la invención, composiciones farmacéuticas que comprenden el anticuerpo biespecífico según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por un antígeno tumoral, uso del anticuerpo biespecífico o composiciones farmacéuticas del mismo para tratar enfermedades o trastornos mediados por un antígeno tumoral, y el uso del anticuerpo biespecífico según la invención y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por un antígeno tumoral.
ARP240100594A 2023-03-10 2024-03-08 Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo AR132099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2023105614A RU2023105614A (ru) 2023-03-10 Выделенное биспецифическое антитело, которое специфически связывается с CD3 и опухолевым антигеном, и его применение

Publications (1)

Publication Number Publication Date
AR132099A1 true AR132099A1 (es) 2025-05-28

Family

ID=92756228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100594A AR132099A1 (es) 2023-03-10 2024-03-08 Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo

Country Status (11)

Country Link
EP (1) EP4676972A1 (es)
KR (1) KR20250155062A (es)
CN (1) CN120858118A (es)
AR (1) AR132099A1 (es)
AU (1) AU2024237201A1 (es)
CO (1) CO2025012267A2 (es)
DO (1) DOP2025000224A (es)
IL (1) IL323119A (es)
MX (1) MX2025010576A (es)
TW (1) TW202440632A (es)
WO (1) WO2024191322A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2017353427A1 (en) * 2016-11-02 2019-05-16 Bristol-Myers Squibb Company Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma

Also Published As

Publication number Publication date
CO2025012267A2 (es) 2026-01-23
KR20250155062A (ko) 2025-10-29
DOP2025000224A (es) 2025-11-16
IL323119A (en) 2025-11-01
EP4676972A1 (en) 2026-01-14
MX2025010576A (es) 2025-11-03
CN120858118A (zh) 2025-10-28
TW202440632A (zh) 2024-10-16
WO2024191322A1 (en) 2024-09-19
AU2024237201A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
PE20210321A1 (es) Anticuerpos biespecificos contra dll3-cd3
WO2021227307A8 (zh) 抗cd73抗体及其用途
AR111207A1 (es) Anticuerpos anti-lag3
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR110101A1 (es) Miembros de unión (2)
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
PE20240589A1 (es) ANTICUERPOS CD1a Y SU USO
AR132099A1 (es) Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo
AR127635A1 (es) ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO
CL2023003854A1 (es) Anticuerpo biespecífico aislado que se une específicamente a cd47 y pd-l1
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
AR132867A1 (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a axl, y uso del mismo
AR132064A1 (es) Anticuerpos anti-cldn6 y métodos de uso
CR20240559A (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo
CO2023012549A2 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
AR132062A1 (es) Anticuerpos multiespecíficos anti-cd3 y métodos de uso
AR132063A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
AR132041A1 (es) Anticuerpos cd16a y métodos de uso
AR132040A1 (es) Anticuerpos muc1 y cd16a y métodos de uso
MX2024011525A (es) Anticuerpo zip12.
CL2018002690A1 (es) Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017).